中文

Library

PharmaVoice Trendline on Artificial intelligence & machine learning

PharmaVoice Trendline on Artificial intelligence & machine learning

Following the departure of former FDA Commissioner Marty Makary, the agency-level AI strategy he championed faces uncertainty. Although Acting Commissioner Kyle Diamantas stated that AI remains a priority, attrition in key positions such as the Chief AI Officer may cause the FDA's internal AI applications to revert to a fragmented model. Industry expert Tala Fakhouri believes that regulatory policy toward sponsors' use of AI will not change in the short term, but balancing transparency and rulemaking processes will be a future challenge.

By: Kelly Bilodeau

Our partners

PAI银行新闻网 PAI生物制药新闻网 PAI财务资讯新闻网 PAIIT信息新闻网 PAI银行资讯站 PAI社会新闻网 PAI用户调研新闻网 PAI网络安全新闻网 PAIES综合新闻网 PAI基础设施科技新闻网 PAI食品科技新闻网 PAI生鲜百货新闻网 PAI医疗保健新闻网 PAI高等教育新闻网 PAI酒店新闻网 PAI人力资源新新闻网 PAIK12教育新闻网 PAI制造业新闻网 PAI市场营销新闻网 PAI医疗技术新闻网 PAI住宅新闻网 PAI包装行业新闻网 PAI支付行业新闻网 PAI生物技术新闻网 PAI资本预算新闻网 PAI外卖行业新闻网 PAI智慧零售新闻网 PAI智慧城市新闻网 PAI新媒体营销新闻网 PAI供应链新闻网 PAI运输业新闻网 PAI电力储能新闻网 PAI汽车新闻网